TMOi001-A-1

hiPSC-CD34-GFP-3G6

General#

Cell Line

hPSCreg Name TMOi001-A-1
Alternative name(s)
hiPSC-CD34-GFP-3G6
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 22nd May 2019
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Children's Cancer Research Institute St. Anna Kinderkrebsforschung e. V. (CCRI)
Distributors
Derivation country Austria

External Databases

BioSamples SAMEA104619935
Cellosaurus CVCL_UL03

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research: allowed
Clinical: not allowed
Commercial: not allowed
Subclone of

Donor Information#

General Donor Information

Sex female

Phenotype and Disease related information (Donor)

Diseases No disease was diagnosed.
Is the medical history available upon request? No
Is clinical information available? No

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA104619829

Ethics#

Also have a look at the ethics information for the parental line TMOi001-A .
Alternatives to consent
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? DNA vectors in part from GenScript
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No
Constraints for use or distribution

hIPSC Derivation#

General

The source cell information can be found in the parental cell line TMOi001-A.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No
Methods used
PCR, RT-PCR
Notes on reprogramming vector detection negative Southern blot

Vector free reprogramming

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
Accutase
O2 Concentration 3 %
CO2 Concentration 5 %
Medium TeSR™ E8™
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
NANOG
Yes
SOX2
Yes
KLF4
Yes
Score:
Marker Present Absent
mCpG
OCT4
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
Albumin
Yes
Hematopoietic Precursor Cell
Ont Id: CL_0008001
In vitro directed differentiation
Marker Expressed
CD34
Yes
CD45 (PTPRC)
Yes
CD43 (SPN)
Yes
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
ACTA2
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
TUBB3
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46,XX
Karyotyping method: Q-banding

Other Genotyping (Cell Line)

Genetic Modification#

Genetic modifications not related to a disease
CD34 (target)
Gene knock-in
1q32.2
1q32.2
flanking PCRs and Southern blot confirmed correct insertion of IRES-GFP; concomitant expression of GFP along with CD34 upon differentiation toward hemato-endothelial progenitors
CRISPR-associated (CRISPR/Cas) System